Carl read the papersWhat it actually is
Senescent cells stop dividing but refuse to die, and they leak inflammatory signals into the tissue around them. In 2017 a group identified FOXO4 as the pivot that keeps those cells alive, and designed a peptide to disrupt its interaction with p53. In senescent cells that pushes p53 out of the nucleus and triggers apoptosis. In the same paper, normal cells were largely spared, with an 11.7-fold difference in sensitivity between senescent and control human fibroblasts.
DRI stands for D-retro-inverso: the peptide is built from D-amino acids in reverse order, which keeps the shape the target recognises while making it far more resistant to being broken down. It is fused to the HIV-TAT sequence so it can get inside cells. Later structural work showed it binds the disordered transactivation domain of p53, and that the cell-penetrating part contributes to the binding rather than just delivering it.
How it’s thought to work
- FOXO4 to p53 disruption — Interferes with the complex that keeps p53 from doing what it would otherwise do in a senescent cell.
- p53 nuclear exclusion — Pushing p53 out of the nucleus is the step that triggers cell-intrinsic apoptosis in senescent cells.
- Selectivity by state — The effect depends on the cell already being senescent, which is why it is described as a senolytic rather than a cytotoxic.
- Retro-inverso design — D-amino acids in reverse sequence resist breakdown, which is the reason this version exists at all.
What the research says
All of it preclinical. The 2017 Cell paper reported that the peptide neutralised doxorubicin toxicity in mice and restored fitness, fur density and kidney function in both fast-ageing and naturally aged mice, under conditions where it was tolerated. Since then: senescent Leydig cells cleared in aged mice with improvement in age-related testosterone decline, senescent human chondrocytes removed in culture (though that did not improve the cartilage those cells went on to make), apoptosis of senescent keloid fibroblasts, and effects in mouse models of lung fibrosis. And one finding that gets quoted far less often: a 2023 Circulation study found that clearing senescent pulmonary endothelial cells, by several methods including this peptide, worsened pulmonary haemodynamics in mice, and the authors concluded that removing those particular senescent cells may be harmful. There are no human studies and no registered clinical trial of FOXO4-DRI.
- 2017 Cell paper: targeted apoptosis of senescent cells restored fur density, fitness and renal function in aged mice.
- Structural work in 2025 confirmed the target is the disordered transactivation domain of p53, with the HIV-TAT tail contributing to binding.
- Aged mouse studies report improvement in age-related testosterone decline through clearance of senescent Leydig cells.
- A 2023 Circulation study found senolytic clearance, this peptide included, worsened pulmonary haemodynamics in mice.
- No human trial, no human dose, no human safety data. A ClinicalTrials.gov search returns zero records.
Reported protocols
These are the doses the peptide community actually reports running (Reddit & forums), alongside published research — logged for education, not as a recommendation to use.
| Parameter | Commonly reported range |
|---|---|
| Human dose | Not established. No study has given this peptide to a person, so there is no dose, no schedule, no route and no safety ceiling. Numbers circulating online are extrapolated from mouse work by people selling it |
| Animal dosing | The published mouse work used three doses of 5 mg/kg given every other day, intravenously in the chemotherapy experiments and into the abdominal cavity in the aged-mouse and Leydig cell work. Mouse mg/kg figures do not convert into a human protocol and are quoted here only to show what the data actually is |
| Route | Intravenous or intraperitoneal in animal work; no established human route |
| Cycle | Senolytics in the literature are given in short pulses rather than daily, because the idea is to clear a population of cells and stop, but no human pulse schedule exists |
| Community dose | Not established. Figures on vendor pages are mouse extrapolations, not reports from people who have written up what they did |
| Carl's note | The useful tip is the thing people skip: a senolytic deletes cells. If it works, it is not reversible by stopping. |
Common use cases
| Goal | Community protocol notes |
|---|---|
| Research only | cell culture and animal models of senescence. That is the entire honest list |
| Not an anti-ageing protocol | there is no human protocol to run, and the mouse results are not a substitute for one |
| Not for use alongside chemotherapy | the 2017 paper modelled doxorubicin toxicity in mice; anyone in cancer treatment needs their oncologist, not a research peptide |
Mixing it (reconstitution)
Freeze-dried peptides must be reconstituted with bacteriostatic water before they can be measured. Carl’s calculator turns “mg in the vial + ml of water + target dose” into “units on the syringe” — and tells you how long the vial lasts.
→ Open the Reconstitution Calculator
Injection & handling
There is no human injection protocol, and any site that gives you one has made it up. No published study has put this peptide into a person, so there is no established route, dose, frequency or interval, and no data on what happens to a human who takes it. It is worth saying why that matters more here than with most entries: this compound is designed to make cells die, and it works through p53, the most studied tumour suppressor there is. Its selectivity has been shown in dishes and mice and nowhere else, and whatever it clears does not come back when you stop. Nothing about reconstitution technique fixes the absence of a dose.
Stacks it appears in
- With other senolytics — Dasatinib and quercetin come up in the same conversations. Those at least have small first-in-human pilot studies behind them, in pulmonary fibrosis and diabetic kidney disease; this does not.
- With Epithalon — Grouped together as anti-ageing compounds and mechanistically unrelated. There is no data for the combination in anything.
Sources
- Baar MP et al. Targeted apoptosis of senescent cells restores tissue homeostasis in response to chemotoxicity and aging. Cell 2017 (PMID 28340339, PMC5556182)
- Bourgeois B et al. The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI. Nat Commun 2025 (PMID 40593617, PMC12216184)
- Born E et al. Eliminating senescent cells can promote pulmonary hypertension development and progression. Circulation 2023 (PMID 36515093)
- Zhang C et al. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice. Aging (Albany NY) 2020 (PMID 31959736, PMC7053614)
- Huang Y et al. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes. Front Bioeng Biotechnol 2021 (PMID 33996787)
- Justice JN et al. Senolytics in idiopathic pulmonary fibrosis: results from a first-in-human, open-label, pilot study. EBioMedicine 2019 (PMID 30616998)
- ClinicalTrials.gov search for 'FOXO4-DRI' (0 records)
- SAHPRA registered health products register (no FOXO4 product)
- SAHPRA, Peptide Products public information page (May 2026)
- WADA 2026 Prohibited List, S0 non-approved substances
